Motexafin gadolinium

N/A

Report date: 2023/07/24 20:00:30
NME

Base Information

Drug NameMotexafin gadolinium
Drug Alias Name莫特沙芬钆Gadolinium (III) texaphyrinGadolinium texaphyrinXcytrinGd-Tex +[10] 
ClassificationSmall moleculesDiagnostic agent (In vivo)
Mechanisms of ActionThioredoxin reductase inhibitors
TargetsThioredoxin reductase
Therapy Area/IndicationsBrain metastasesCNS Embryonal TumorSolid tumours +[41] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPharmacyclics Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharmacyclics LlcOhsu Knight Cancer InstituteUniversity Of Pittsburgh +[8] 
Active IndicationsN/A
Inactive IndicationsBrain metastasesCNS Embryonal TumorSolid tumours +[41] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG